Vistagen Therapeutics Inc [NASDAQ: VTGN] traded at a low on Tuesday, posting a -0.78 loss after which it closed the day’ session at $2.55.
The results of the trading session contributed to over 293011 shares changing hands. Over the past one week, the price volatility of Vistagen Therapeutics Inc stands at 8.51% while the volatility over the past one month is 6.26%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for VTGN stock reached $71.00 million, with 27.06 million shares outstanding and 25.10 million shares in the current float. Compared to the average trading volume of 239.05K shares, VTGN reached a trading volume of 293011 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vistagen Therapeutics Inc [VTGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTGN shares is $13.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTGN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Vistagen Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 07, 2023. The new note on the price target was released on August 07, 2023, representing the official price target for Vistagen Therapeutics Inc stock.
The Average True Range (ATR) for Vistagen Therapeutics Inc is set at 0.16, with the Price to Sales ratio for VTGN stock in the period of the last 12 months amounting to 80.69. The Price to Book ratio for the last quarter was 0.74, with the Price to Cash per share for the same quarter was set at 3.50.
How has VTGN stock performed recently?
Vistagen Therapeutics Inc [VTGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.94. With this latest performance, VTGN shares dropped by -1.16% in over the last four-week period, additionally sinking by -21.54% over the last 6 months – not to mention a drop of -51.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 47.48, with the RSI for the last a single of trading hit 51.89, and the three-weeks RSI is set at 45.29 for Vistagen Therapeutics Inc [VTGN]. The present Moving Average for the last 50 days of trading for this stock 2.79, while it was recorded at 2.44 for the last single week of trading, and 3.58 for the last 200 days.
Vistagen Therapeutics Inc [VTGN]: Deeper insight into the fundamentals
Vistagen Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.29 and a Current Ratio set at 13.29.
Insider trade positions for Vistagen Therapeutics Inc [VTGN]
There are presently around $53.63%, or 53.76%% of VTGN stock, in the hands of institutional investors.
